Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets
NCT ID: NCT05111028
Last Updated: 2021-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
10 participants
INTERVENTIONAL
2020-11-20
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Period 1
Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
Autologous Room Temperature stored Platelet transfusion
An autologous transfusion of platelets stored at 22°C for 7 days.
Autologous Cold Stored Platelet transfusion
An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
Period 2
Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
Autologous Room Temperature stored Platelet transfusion
An autologous transfusion of platelets stored at 22°C for 7 days.
Autologous Cold Stored Platelet transfusion
An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Room Temperature stored Platelet transfusion
An autologous transfusion of platelets stored at 22°C for 7 days.
Autologous Cold Stored Platelet transfusion
An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-59 years old
* All sexes
* Temperature \<99.6 F
* Resting blood pressure: systolic \<181 mmHg, diastolic \<101 mmHg
* Resting heart rate: 40 - 100 beats per minute
* Weight: \>109 lb
* Hematocrit: \>34% for female subjects, \>37% for male subjects. \<56% for all subjects.
* Platelet count able to achieve target platelet yield per apheresis machine configuration parameters
* Subjects must be able to read, understand and sign the informed consent document and commit to the study follow-up schedule. The ability to read and speak English is required for participation
* Subject must agree to avoid taking any aspirin or aspirin-containing drugs (e.g., Alka-Seltzer®, Bufferin®, Excedrin®) or NSAIDs (e.g.,Feldene®, Motrin®, Aleve®, Advil®) or other drugs known to significantly affect platelet function throughout their study participation determined by PI
* Subjects must have "good veins" for apheresis platelet collection and drawing blood samples
* Women of child-bearing potential must agree to use an effective method of contraception during the course of the study. The following methods of contraception will be considered 'effective' when self-reported by subject; abstinence, intrauterine contraception devices, hormonal methods, barrier methods or history of sterilization
* Subject has phone and e-mail for contact and notification, and is able to come to the research site for study visits
Exclusion Criteria
2. Active immune/inflammatory condition (e.g. gout, systemic lupus erythematosus, allograft rejection).
3. History of heart disease, including endorsement of shortness of breath with mild exertion (at the discretion of the PI).
4. History of significant liver, kidney, GI, blood, endocrine/metabolic, autoimmune or pulmonary disease, untreated hypertension and or metabolic syndrome (at the discretion of the PI).
5. Diabetes Mellitus.
6. Cancer of any kind (exceptions being basal or squamous cell cancers of the skin), under treatment or resolved.
7. History of bleeding events, family history of bleeding events, or known genetic disorder with bleeding diathesis.
8. A family history of venous or arterial thrombosis before the age of 50 in first degree relatives.
9. A personal history of DVT, venous or arterial thrombosis, blood clots or stroke.
10. History of or currently prescribed antiplatelet therapies \[such as clopidogrel (Plavix), ticlopidine (Ticlid) or Ticagrelor (Brilinta)\] and/or anticoagulant therapies \[such as heparin, enoxaparin (Lovenox), warfarin (Coumadin), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), rivaroxaban (Xarelto)\].
11. Subject has taken any aspirin or aspirin-containing drugs (e.g., Alka-Seltzer®, Bufferin®, Excedrin®) or NSAIDs (e.g.,Feldene®, Motrin®, Aleve®, Advil®) or other drugs known to significantly affect platelet function within 14 days prior to screening as determined by PI.
12. Chronic NSAID therapy.
13. Chronic steroid therapy.
14. Known allergy to aspirin.
15. Current drug or alcohol dependence by subject's declaration.
16. Currently pregnant or nursing as assessed during interview. A urine pregnancy test prior to apheresis is required for women of childbearing potential.
17. Subject plans to participate in contact sports during study/observational period such as boxing, rugby, American football, soccer, or other risky recreational hobbies at the discretion of the investigator.
18. Unwilling or unable to comply with the protocol in the opinion of the investigator.
19. Participation in an experimental drug/device study within the past 30 days (other than this study). Subjects who have received an infusion on this study may not be re-enrolled.
20. Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment
18 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Department of Defense
FED
Bloodworks
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moritz Stolla, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Bloodworks
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bloodworks Northwest Research Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-01
Identifier Type: -
Identifier Source: org_study_id